Patents by Inventor Sida Shen

Sida Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20260116861
    Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Application
    Filed: September 25, 2025
    Publication date: April 30, 2026
    Applicants: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of Illinois
    Inventors: Alejandro VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
  • Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors
    Patent number: 12522572
    Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Grant
    Filed: March 27, 2024
    Date of Patent: January 13, 2026
    Assignees: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of Illinois
    Inventors: Alejandro Villagra, Alan P. Kozikowski, Sida Shen
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20250230172
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: July 17, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20250034170
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: January 30, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen, Jeremiah Brittin, Zhiquan Lei, Greg Sheyka
  • ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20240343697
    Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Application
    Filed: March 27, 2024
    Publication date: October 17, 2024
    Applicants: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of Illinois
    Inventors: Alejandro VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20240262832
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease. Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease. Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 8, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors
    Patent number: 12024493
    Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: July 2, 2024
    Assignees: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of Illinois
    Inventors: Alejandro Villagra, Alan P. Kozikowski, Sida Shen
  • (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-ENECARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE
    Publication number: 20240174596
    Abstract: Disclosed are amino, fluoro-substituted cyclopentene carboxylic acid compounds. The disclosed compounds and compositions thereof may be utilized in methods for modulating human ornithine ?-aminotransferase (hOAT) activity, including methods for treating diseases or disorders associated with to hOAT activity or expression such as cell proliferative diseases and disorders.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 30, 2024
    Inventors: Richard B. Silverman, Sida Shen
  • 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
    Patent number: 11993569
    Abstract: Disclosed are cyclopentene compounds for use as inhibitors of aminotransferases such as gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-amino-4-halocyclopente carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: May 28, 2024
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Sida Shen
  • SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20230250054
    Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits comprising histone deacetylase (HD AC) inhibitors of formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, L1, L2, m, n, p, X, Y, and Z are as defined in the specification, including methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and/or chemotherapy in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 10, 2023
    Inventors: Sida SHEN, Alejandro VILLAGRA, Alan KOZIKOWSKI
  • Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors
    Patent number: 11472780
    Abstract: The present disclosure provides compounds represented by Formula (I): and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 18, 2022
    Assignees: The George Washington University, The Board of Trustees ofthe University of Illinois
    Inventors: Alejandro Villagra, Alan P. Kozikowski, Sida Shen
  • ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20220153709
    Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Applicants: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, The Board of Trustees of the University of Illinois
    Inventors: Alejandro VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
  • 3-AMINO-4-HALOCYCLOPENTENE CARBOXYLIC ACIDS AS INACTIVATORS OF AMINOTRANSFERASES
    Publication number: 20210238120
    Abstract: Disclosed are cyclopentene compounds for use as inhibitors of aminotransferases such as gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-amino-4-halocyclopente carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: January 22, 2021
    Publication date: August 5, 2021
    Inventors: Richard B. Silverman, Sida Shen
  • Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors
    Publication number: 20200115350
    Abstract: The present disclosure provides compounds represented by Formula (I): and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 16, 2020
    Inventors: ALEJANDRO VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
  • Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors
    Patent number: 10456394
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: October 29, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Sida Shen, Joel Bergman, Irina Gaisina
  • 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
    Patent number: 10435400
    Abstract: The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 8, 2019
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Yunzhou Jin, Fusheng Zhou, Jing Xie, Sida Shen, Yi Hu, Wei Liu, Qiang Lv
  • TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
    Publication number: 20190255046
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Application
    Filed: February 15, 2017
    Publication date: August 22, 2019
    Applicant: The Board of Trustees of the University of Illinos
    Inventors: Alan KOZIKOWSKI, Sida SHEN, Joel BERGMAN, Irina GAISINA
  • 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
    Patent number: 10227324
    Abstract: Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 12, 2019
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Sida Shen, Xiaojing Ni, Zhiyuan Zhang, Zheng Yang, Xiangyu He, Weiwei Wang, Fusheng Zhou
  • 2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
    Publication number: 20170349568
    Abstract: Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 7, 2017
    Inventors: Sida SHEN, Xiaojing NI, Zhiyuan ZHANG, Zheng YANG, Xiangyu HE, Weiwei WANG, Fusheng ZHOU
  • 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM
    Publication number: 20170008889
    Abstract: The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.
    Type: Application
    Filed: February 13, 2015
    Publication date: January 12, 2017
    Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong LAN, Yunzhou JIN, Fusheng ZHOU, Jing XIE, Sida SHEN, Yi HU, Wei LIU, Qiang LV